BIO-Europe 2014: Interview with Tom Watson, Clinigen

July 7, 2015
The more pharma and biotech companies focus on novel molecules for unmet medical needs and rare diseases, the greater the demand for early access to these promising drugs, well ahead of market authorization. Tom Watson of Clinigen discusses how his company's "Early Access Program" is helping to bring novel drugs in development to patients who are running out of treatment options. Find more videos and articles at http://www.partnering360.com/insight For more information on BIO-Europe, visit our webpage: http://www.ebdgroup.com/beu/index.php
Previous Video
BIO-Europe 2014: Interview with Jochen Maas, Sanofi
BIO-Europe 2014: Interview with Jochen Maas, Sanofi

Partnering is still the deal in biotech. Jochen Maas of Sanofi discusses the critical role partnering meeti...

Next Video
BIO-Europe 2014: Interview with Christian Hordo, Genentech
BIO-Europe 2014: Interview with Christian Hordo, Genentech

For Genentech, partnering early is the ideal. Christian Hordo of Genentech discusses how the company's scie...